Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

A young man who allegedly died a “horrific” death after consuming allegedly contaminated antibiotics he bought at a ...

Anthropic announced it received an additional $4 billion investment from Amazon as they deepened their partnership with AWS ...

U.S. Sen. Ron Johnson has threatened to issue a subpoena when he becomes chairman of the Permanent Subcommittee on ...

A COVID-19 study in Britain looked at the medical records of 1.7 million children but did not conclude the same number of ...

In today's biotech news, Prime Editing's CEO promises aggressive defense of patents; Novartis acquires a gene editing startup ...

Fewer than 18% of U.S. adults have opted to receive the newly updated COVID-19 vaccine, according to the latest data from the ...

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...